|
US4873088A
(en)
*
|
1983-09-06 |
1989-10-10 |
Liposome Technology, Inc. |
Liposome drug delivery method and composition
|
|
JPS6058915A
(ja)
*
|
1983-09-12 |
1985-04-05 |
Fujisawa Pharmaceut Co Ltd |
薬物含有脂質小胞体製剤
|
|
EP0152379A3
(de)
*
|
1984-02-15 |
1986-10-29 |
Ciba-Geigy Ag |
Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
|
|
CH668554A5
(de)
*
|
1984-04-09 |
1989-01-13 |
Sandoz Ag |
Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
|
|
US5283122A
(en)
*
|
1984-04-19 |
1994-02-01 |
University Of Tennessee Research Corporation |
Fused liposome and acid induced method for liposome fusion
|
|
CA1260393A
(en)
*
|
1984-10-16 |
1989-09-26 |
Lajos Tarcsay |
Liposomes of synthetic lipids
|
|
US4921706A
(en)
*
|
1984-11-20 |
1990-05-01 |
Massachusetts Institute Of Technology |
Unilamellar lipid vesicles and method for their formation
|
|
JPS62501631A
(ja)
*
|
1985-01-11 |
1987-07-02 |
ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア |
リポソ−ムの保持法
|
|
US4740375A
(en)
*
|
1985-02-25 |
1988-04-26 |
Technology Unlimited, Inc. |
Gelcores
|
|
US4736051A
(en)
*
|
1985-03-20 |
1988-04-05 |
Kao Corporation |
Process for the preparation of an alkali metal salt of a diester phosphoric acid
|
|
US5622713A
(en)
*
|
1985-09-17 |
1997-04-22 |
The Regents Of The University Of California |
Method of detoxifying animal suffering from overdose
|
|
IE58981B1
(en)
*
|
1985-10-15 |
1993-12-15 |
Vestar Inc |
Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
|
|
MY101125A
(en)
*
|
1985-12-23 |
1991-07-31 |
Kao Corp |
Gel-like emulsion and o/w emulsions obtained from gel-like emulsion
|
|
US4923854A
(en)
*
|
1986-01-22 |
1990-05-08 |
The Liposome Company, Inc. |
Solubilization of hydrophobic materials using lysophospholipid
|
|
US4888288A
(en)
*
|
1986-01-30 |
1989-12-19 |
Becton Dickinson And Company |
Vesicles resistant to enzyme lysis and use thereof in an enzyme assay
|
|
US5252263A
(en)
*
|
1986-06-16 |
1993-10-12 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
|
WO1987007530A1
(en)
*
|
1986-06-16 |
1987-12-17 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
|
US5204112A
(en)
*
|
1986-06-16 |
1993-04-20 |
The Liposome Company, Inc. |
Induction of asymmetry in vesicles
|
|
JPS63182029A
(ja)
*
|
1987-01-22 |
1988-07-27 |
Agency Of Ind Science & Technol |
リポソ−ム
|
|
CA1323306C
(en)
*
|
1987-03-05 |
1993-10-19 |
Mircea C. Popescu |
Pharmacological agent-lipid solution preparation
|
|
MX9203808A
(es)
*
|
1987-03-05 |
1992-07-01 |
Liposome Co Inc |
Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
|
|
US5154930A
(en)
*
|
1987-03-05 |
1992-10-13 |
The Liposome Company, Inc. |
Pharmacological agent-lipid solution preparation
|
|
CA1338702C
(en)
*
|
1987-03-05 |
1996-11-12 |
Lawrence D. Mayer |
High drug:lipid formulations of liposomal- antineoplastic agents
|
|
US4963297A
(en)
*
|
1987-12-22 |
1990-10-16 |
The Liposome Company, Inc. |
Spontaneous vesticulation of multilamellar liposomes
|
|
FR2616328B1
(fr)
*
|
1987-06-12 |
1990-03-02 |
Moet Hennessy Rech |
Composition a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un extrait de murier, ou au moins une flavone, en particulier une kuwanone et composition pharmaceutique, notamment dermatologique, a activite depigmentante, ou anti-inflammatoire, ou cosmetique, l'incorporant
|
|
AU618972B2
(en)
*
|
1987-10-06 |
1992-01-16 |
Houston Biotechnology Incorporated |
Phosphatidyl treatment of viral disease
|
|
US4946683A
(en)
*
|
1987-11-18 |
1990-08-07 |
Vestar, Inc. |
Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes
|
|
CA1330199C
(en)
*
|
1987-12-22 |
1994-06-14 |
Thomas D. Madden |
Spontaneous vesiculation of multilamellar liposomes
|
|
US5269979A
(en)
*
|
1988-06-08 |
1993-12-14 |
Fountain Pharmaceuticals, Inc. |
Method for making solvent dilution microcarriers
|
|
US5133965A
(en)
*
|
1988-06-08 |
1992-07-28 |
Fountain Pharmaceuticals, Inc. |
Dressing material having adsorbed thereon a solvent dilution microcarrier precursor solution
|
|
FR2638639A1
(fr)
*
|
1988-11-08 |
1990-05-11 |
Parincos Parfumerie Cosmet Int |
Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique
|
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
|
US5015483A
(en)
*
|
1989-02-09 |
1991-05-14 |
Nabisco Brands, Inc. |
Liposome composition for the stabilization of oxidizable substances
|
|
US5139803A
(en)
*
|
1989-02-09 |
1992-08-18 |
Nabisco, Inc. |
Method and liposome composition for the stabilization of oxidizable substances
|
|
US4994440A
(en)
*
|
1989-02-13 |
1991-02-19 |
Creaven Patrick J |
Method for the treatment of renal cell carcinoma
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
IL94103A0
(en)
*
|
1989-04-25 |
1991-01-31 |
Nattermann A & Cie |
Water-containing formulations with phospholipids,their preparation and application
|
|
DE3919982A1
(de)
*
|
1989-06-19 |
1990-12-20 |
Liedtke Pharmed Gmbh |
Orale lipidarzneiform
|
|
US5290563A
(en)
*
|
1989-07-27 |
1994-03-01 |
Laboratoire Des Stallergenes |
Method for combining a mixture of heterogeneous substances with liposomes
|
|
GB8918879D0
(en)
*
|
1989-08-18 |
1989-09-27 |
Danbiosyst Uk |
Pharmaceutical compositions
|
|
DE4005711C1
(da)
*
|
1990-02-23 |
1991-06-13 |
A. Nattermann & Cie Gmbh, 5000 Koeln, De |
|
|
DE4013632A1
(de)
*
|
1990-04-27 |
1991-10-31 |
Max Planck Gesellschaft |
Liposomen mit positiver ueberschussladung
|
|
US5165994A
(en)
*
|
1990-06-05 |
1992-11-24 |
University Of Delaware |
Spontaneous equilbrium surfactant vesicles
|
|
DE4018767A1
(de)
*
|
1990-06-12 |
1991-12-19 |
Braun Melsungen Ag |
Wirkstofffreie liposomen zur behandlung von atherosklerose
|
|
EP0467838A3
(en)
*
|
1990-07-17 |
1992-09-02 |
Ciba-Geigy Ag |
Process for preparing an injectable liposome dispersion
|
|
CA2046830C
(en)
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
|
|
FR2674128A1
(fr)
*
|
1991-03-19 |
1992-09-25 |
Patrinove |
"vecteurs de structure capsulaire" et leurs applications dans le transport de substances ou principes actifs.
|
|
US6764693B1
(en)
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
|
US5720973A
(en)
*
|
1993-02-18 |
1998-02-24 |
Knoll Aktiengesellschaft |
Preparation of colloidal aqueous solutions of active substances of low solubility and a lipid therefor
|
|
GB9320668D0
(en)
*
|
1993-10-07 |
1993-11-24 |
Secr Defence |
Liposomes containing particulare materials
|
|
US5840328A
(en)
*
|
1994-01-11 |
1998-11-24 |
The Liposome Company, Inc. |
Treatment using arachidonic acid metabolite and particulate formulations
|
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
IT1270678B
(it)
*
|
1994-10-20 |
1997-05-07 |
Bayer Ag |
Liposomi al chetoprofen
|
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
|
US20020048596A1
(en)
*
|
1994-12-30 |
2002-04-25 |
Gregor Cevc |
Preparation for the transport of an active substance across barriers
|
|
US7517858B1
(en)
*
|
1995-06-07 |
2009-04-14 |
The Regents Of The University Of California |
Prodrugs of pharmaceuticals with improved bioavailability
|
|
US20040208922A1
(en)
*
|
1995-06-07 |
2004-10-21 |
The Regents Of The University Of California |
Method for loading lipid like vesicles with drugs or other chemicals
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6183774B1
(en)
|
1996-01-31 |
2001-02-06 |
Collaborative Laboratories, Inc. |
Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
|
|
US5874105A
(en)
*
|
1996-01-31 |
1999-02-23 |
Collaborative Laboratories, Inc. |
Lipid vesicles formed with alkylammonium fatty acid salts
|
|
US6071535A
(en)
*
|
1996-01-31 |
2000-06-06 |
Collaborative Laboratories, Inc. |
Lipid vesicles formed with alkylammonium fatty acid salts
|
|
US6723531B2
(en)
*
|
1996-04-05 |
2004-04-20 |
The Salk Institute For Biological Studies |
Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
US5766877A
(en)
*
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
|
PT939804E
(pt)
|
1996-10-25 |
2005-11-30 |
Human Genome Sciences Inc |
Neutroquina alfa
|
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
|
US6156728A
(en)
*
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
|
US5919656A
(en)
*
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
|
US5935572A
(en)
*
|
1997-01-10 |
1999-08-10 |
Collaborative Laboratories, Inc. |
Composition containing protease separate from glycosidase for removing nits in treating lice infestation
|
|
US5827532A
(en)
*
|
1997-01-31 |
1998-10-27 |
The Reagents Of The University Of California |
Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
|
|
US6103706A
(en)
*
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
|
AU7801998A
(en)
|
1997-05-30 |
1998-12-30 |
Human Genome Sciences, Inc. |
32 human secreted proteins
|
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
|
US6300488B1
(en)
|
1997-07-10 |
2001-10-09 |
The Salk Institute For Biological Studies |
Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
AU9221698A
(en)
*
|
1997-09-04 |
1999-03-22 |
Biozone Laboratories, Inc. |
Oral liposomal delivery system
|
|
US6165997A
(en)
*
|
1997-11-20 |
2000-12-26 |
Statens Serum Institut |
Phospholipids having antimicrobial activity with or without the presence of antimicrobials
|
|
DE69841751D1
(en)
*
|
1997-11-21 |
2010-08-12 |
Human Genome Sciences Inc |
Chemokin alpha-5
|
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
|
CA2318857C
(en)
|
1998-02-04 |
2013-09-24 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
|
CA2322792C
(en)
|
1998-03-17 |
2010-09-14 |
Genentech, Inc. |
Polypeptides homologous to vegf and bmp1
|
|
US6949528B1
(en)
*
|
1998-03-18 |
2005-09-27 |
Goddard John G |
Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
|
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
|
US6333318B1
(en)
*
|
1998-05-14 |
2001-12-25 |
The Salk Institute For Biological Studies |
Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
|
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
|
KR100638150B1
(ko)
*
|
1998-12-23 |
2006-10-26 |
이데아 악티엔게젤샤프트 |
생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제
|
|
ATE216875T1
(de)
|
1999-01-27 |
2002-05-15 |
Idea Ag |
Nichtinvasive impfung durch die haut
|
|
ES2173679T3
(es)
|
1999-01-27 |
2002-10-16 |
Idea Ag |
Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
|
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
|
JP5000804B2
(ja)
*
|
1999-02-03 |
2012-08-15 |
アムジエン・インコーポレーテツド |
免疫応答に関与する新規ポリペプチド
|
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
CA2363779A1
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
|
WO2001001962A1
(en)
*
|
1999-07-05 |
2001-01-11 |
Idea Ag. |
A method for the improvement of transport across adaptable semi-permeable barriers
|
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7057015B1
(en)
|
1999-10-20 |
2006-06-06 |
The Salk Institute For Biological Studies |
Hormone receptor functional dimers and methods of their use
|
|
US6372722B1
(en)
|
2000-01-19 |
2002-04-16 |
Genteric, Inc. |
Method for nucleic acid transfection of cells
|
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
|
US20030171267A1
(en)
|
2000-04-12 |
2003-09-11 |
Rosen Craig A. |
Albumin fusion proteins
|
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
AU7026601A
(en)
|
2000-06-28 |
2002-01-08 |
Amgen Inc |
Thymic stromal lymphopoietin receptor molecules and uses thereof
|
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
|
EP1337634A2
(en)
|
2000-11-28 |
2003-08-27 |
Amgen Inc. |
Novel polypeptides involved in immune response
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
DK2270052T3
(da)
|
2001-06-26 |
2018-07-02 |
Amgen Inc |
Antistoffer mod OPGL
|
|
US6886964B2
(en)
*
|
2001-06-26 |
2005-05-03 |
Allan Gardiner |
Illuminator with filter array and bandwidth controller
|
|
JP4399260B2
(ja)
|
2001-08-24 |
2010-01-13 |
ニューレン ファーマシューティカルズ リミテッド |
神経再生ペプチドおよび脳損傷治療におけるその使用方法
|
|
US7060278B2
(en)
|
2001-08-29 |
2006-06-13 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
|
GB0121709D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
|
IL160983A0
(en)
|
2001-09-24 |
2004-08-31 |
Imp College Innovations Ltd |
Use of pyy for preparation of a medicament for modification of feeding behavior
|
|
WO2003029407A2
(en)
*
|
2001-09-26 |
2003-04-10 |
Merck & Co., Inc. |
Isolated nucleic acid molecules encoding a bacterial uracil transport protein and a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
|
|
EP1930420A1
(en)
|
2001-09-26 |
2008-06-11 |
Merck & Co., Inc. |
Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
|
|
DE10148067A1
(de)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
Hitzesterilisierbare Alkylphosphocholin-Liposome
|
|
DE10148066A1
(de)
*
|
2001-09-28 |
2003-04-24 |
Max Planck Gesellschaft |
Liposome enthaltend (Ether)-Lysolecithine
|
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
|
US20040106773A1
(en)
*
|
2001-10-12 |
2004-06-03 |
Hao Wang |
Human tuberoinfundibular peptide of 39 residues
|
|
CA2462883A1
(en)
|
2001-10-12 |
2003-04-17 |
Schering Corporation |
Use of bispecific antibodies to regulate immune responses
|
|
EP1997829A1
(en)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US8058233B2
(en)
*
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
EP1474163A2
(en)
|
2002-01-10 |
2004-11-10 |
Imperial College Innovations Limited |
Modification of feeding behavior
|
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
|
MXPA04009681A
(es)
|
2002-04-05 |
2005-01-11 |
Amgen Inc |
Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina.
|
|
AU2002304965A1
(en)
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
DK2213685T3
(da)
|
2002-09-06 |
2014-03-03 |
Medarex Llc |
Terapeutisk anti-IL-1R1-monoklonalt antistof
|
|
KR100489701B1
(ko)
*
|
2002-10-09 |
2005-05-16 |
주식회사 태평양 |
고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
|
|
US7473432B2
(en)
*
|
2002-10-11 |
2009-01-06 |
Idea Ag |
NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
|
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
|
US7285269B2
(en)
|
2002-12-02 |
2007-10-23 |
Amgen Fremont, Inc. |
Antibodies directed to tumor necrosis factor
|
|
CA2511823A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
CN102225194B
(zh)
|
2003-03-12 |
2014-07-16 |
健泰科生物技术公司 |
Bv8和/或EG-VEGF促进造血的用途
|
|
CA2519528C
(en)
|
2003-03-19 |
2016-01-26 |
Abgenix, Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
|
US7291590B2
(en)
|
2003-06-12 |
2007-11-06 |
Queen's University At Kingston |
Compositions and methods for treating atherosclerosis
|
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
KR101254371B1
(ko)
|
2003-07-18 |
2013-05-02 |
암젠 프레몬트 인코포레이티드 |
간세포 성장인자에 결합하는 분리된 항체
|
|
DK2274978T3
(da)
|
2003-09-12 |
2015-06-15 |
Ipsen Biopharmaceuticals Inc |
Fremgangsmåder til behandling af en insulin-lignende vækstfaktor-I(IGF-I)-mangel
|
|
EP1684791A4
(en)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
|
|
AU2005207998A1
(en)
*
|
2004-01-05 |
2005-08-11 |
Biotech Studio, Llc |
Biotherapeutics, diagnostics and research reagents
|
|
KR20070007086A
(ko)
*
|
2004-02-02 |
2007-01-12 |
암브룩스, 인코포레이티드 |
변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
|
|
MXPA06010673A
(es)
|
2004-03-19 |
2007-06-20 |
Amgen Inc |
Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
|
|
EP1726647B1
(en)
|
2004-03-19 |
2015-01-07 |
GenomIdea, Inc. |
Gene promoting vascular endothelial cell growth
|
|
CA2560889A1
(en)
*
|
2004-03-23 |
2005-10-13 |
Sanjay D. Khare |
Monoclonal antibodies specific for human ox40l (cd 134l)
|
|
WO2005095633A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Queen's University At Kingston |
A cell culture system for modelling serum amyloid a amyloidogenesis and identifying amyloid modulating compounds
|
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
|
NZ551335A
(en)
|
2004-06-18 |
2010-03-26 |
Ambrx Inc |
Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
|
|
ATE501252T1
(de)
|
2004-06-22 |
2011-03-15 |
Univ Illinois |
Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
|
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
|
CA2569381A1
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
AU2005267722B2
(en)
|
2004-08-04 |
2009-10-08 |
Amgen Inc. |
Antibodies to Dkk-1
|
|
AU2005277384B2
(en)
|
2004-08-17 |
2011-11-17 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
|
WO2006037182A1
(en)
|
2004-10-06 |
2006-04-13 |
Agri-Biotech Pty Ltd |
Antibody production method
|
|
US20080095722A1
(en)
*
|
2004-11-12 |
2008-04-24 |
Idea Ag |
Extended Surface Aggregates in the Treatment of Skin Conditions
|
|
WO2006055638A2
(en)
|
2004-11-17 |
2006-05-26 |
Abgenix, Inc. |
Fully human monoclonal antibodies to il-13
|
|
US7572444B2
(en)
|
2004-12-20 |
2009-08-11 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
|
RU2394839C2
(ru)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Антитела против ангиопоэтина-2 и их применение
|
|
MX2007007591A
(es)
|
2004-12-22 |
2007-07-25 |
Ambrx Inc |
Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
|
|
EP1828224B1
(en)
|
2004-12-22 |
2016-04-06 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
NZ584597A
(en)
|
2004-12-22 |
2011-09-30 |
Ambrx Inc |
Modified human growth hormone
|
|
CN103520735B
(zh)
|
2004-12-22 |
2015-11-25 |
Ambrx公司 |
包含非天然编码的氨基酸的人生长激素配方
|
|
BRPI0519568C8
(pt)
*
|
2004-12-22 |
2022-06-14 |
Ambrx Inc |
Aminoacil-trna sintetase (rs), composições que compreendem a dita aminoacil-trna sintetase, célula de levedura, célula fúngica, célula não eucariótica, vetor que codifica uma rs, polinucleotídeo e ainda método para produzir um polipeptídeo em uma célula com um aminoácido selecionado em uma posição especificada
|
|
US20060154285A1
(en)
*
|
2004-12-29 |
2006-07-13 |
Robishaw Janet D |
Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
|
|
US7566772B2
(en)
|
2005-01-26 |
2009-07-28 |
Amgen Fremont Inc. |
Antibodies against interleukin-1β
|
|
EP1868628B1
(en)
*
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
|
JP2008538354A
(ja)
*
|
2005-04-08 |
2008-10-23 |
キメリクス，インコーポレイテッド |
ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
|
|
JP2008540571A
(ja)
*
|
2005-05-12 |
2008-11-20 |
ウィスコンシン・アルムニ・リサーチ・ファウンデーション |
Ｐｉｎ１の遮断は活性化した免疫細胞によるサイトカイン産生を防ぐ
|
|
CA2609205A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
|
GB0511986D0
(en)
*
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
MX2007015476A
(es)
|
2005-06-14 |
2008-02-25 |
Amgen Inc |
Formulaciones de proteina autoamortiguadoras.
|
|
KR20140139618A
(ko)
|
2005-06-21 |
2014-12-05 |
조마 (유에스) 엘엘씨 |
ＩＬ-１β 결합성 항체 및 그의 단편
|
|
SG196835A1
(en)
|
2005-07-18 |
2014-02-13 |
Amgen Inc |
Human anti-b7rp1 neutralizing antibodies
|
|
CN101600475A
(zh)
|
2005-07-27 |
2009-12-09 |
佛罗里达大学研究基金会有限公司 |
修正蛋白质错误折叠的小型化合物及其使用
|
|
EP1937824B1
(en)
*
|
2005-08-18 |
2013-03-13 |
Ambrx, Inc. |
COMPOSITIONS OF tRNA AND USES THEREOF
|
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
|
NZ567234A
(en)
*
|
2005-11-08 |
2011-09-30 |
Ambrx Inc |
Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
|
|
EP1957115B8
(en)
|
2005-11-10 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
|
DK2339014T3
(da)
|
2005-11-16 |
2015-07-20 |
Ambrx Inc |
Fremgangsmåder og sammensætninger omfattende ikke-naturlige aminosyrer
|
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
|
US8158588B2
(en)
|
2005-12-05 |
2012-04-17 |
Simon Delagrave |
Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
|
|
RS52357B
(en)
|
2005-12-13 |
2012-12-31 |
Medimmune Limited |
BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE
|
|
EP1969003B8
(en)
|
2005-12-14 |
2010-11-10 |
Hermo Pharma Ltd. |
Uses of a NEUROTROPHIC FACTOR PROTEIN
|
|
SG10201405661QA
(en)
*
|
2005-12-14 |
2014-10-30 |
Ambrx Inc |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CN101370519B
(zh)
|
2005-12-15 |
2013-07-24 |
阿斯利康(瑞典)有限公司 |
治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
|
|
BRPI0621124A2
(pt)
|
2005-12-22 |
2011-11-29 |
Genentech Inc |
métodos para recuperação de uma proteìna de ligação à heparina
|
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
AU2007248483A1
(en)
|
2006-05-03 |
2007-11-15 |
Geisinger Clinic |
Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
|
|
WO2007136679A2
(en)
|
2006-05-17 |
2007-11-29 |
Ludwig Institute For Cancer Research |
Targeting vegf-b regulation of fatty acid transporters to modulate human diseases
|
|
US8124743B2
(en)
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
|
WO2008014426A2
(en)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
EP2054437A2
(en)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
|
WO2008030558A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
KR20090052360A
(ko)
*
|
2006-09-08 |
2009-05-25 |
암브룩스, 인코포레이티드 |
척추동물 세포에서의 서프레서 ｔＲＮＡ 전사
|
|
US9133495B2
(en)
*
|
2006-09-08 |
2015-09-15 |
Ambrx, Inc. |
Hybrid suppressor tRNA for vertebrate cells
|
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
|
MX2009006082A
(es)
|
2006-12-08 |
2009-08-18 |
Lexicon Pharmaceuticals Inc |
Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3).
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
JP5645409B2
(ja)
|
2006-12-20 |
2014-12-24 |
ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー |
ＩＬ−１β関連疾患の治療方法
|
|
US9249423B2
(en)
*
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
US8859229B2
(en)
*
|
2007-02-02 |
2014-10-14 |
Yale University |
Transient transfection with RNA
|
|
WO2013106175A1
(en)
|
2011-12-19 |
2013-07-18 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
TWI454479B
(zh)
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
|
DK2068909T3
(da)
|
2007-03-30 |
2012-08-06 |
Ambrx Inc |
Modificerede FGF-21-polypeptider og anvendelse heraf
|
|
KR20100019467A
(ko)
*
|
2007-05-02 |
2010-02-18 |
암브룩스, 인코포레이티드 |
변형된 인터페론 베타 폴리펩티드 및 그의 용도
|
|
WO2008140026A1
(ja)
|
2007-05-11 |
2008-11-20 |
Bizen Chemical Co., Ltd. |
新規のロイコトリエン受容体アンタゴニスト
|
|
US20110206673A1
(en)
|
2007-06-27 |
2011-08-25 |
Liu Dongxu |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
|
PT2188313T
(pt)
|
2007-08-21 |
2017-12-12 |
Amgen Inc |
Proteínas de ligação ao antigénio c-fms humano
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
EP2615113A3
(en)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
|
CA2700723A1
(en)
|
2007-09-26 |
2009-04-02 |
Amgen Inc. |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
MX2010005317A
(es)
*
|
2007-11-20 |
2010-06-02 |
Ambrx Inc |
Polipeptidos de insulina modificados y sus usos.
|
|
RU2018100129A
(ru)
|
2007-12-20 |
2019-02-20 |
Ксома (Сша) Ллс |
Способы лечения подагры
|
|
EP2254582B1
(en)
*
|
2008-01-25 |
2016-01-20 |
Chimerix, Inc. |
Methods of treating viral infections
|
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
TR201904041T4
(tr)
|
2008-06-09 |
2019-04-22 |
Max Planck Gesellschaft |
Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
|
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
ES2654387T3
(es)
|
2008-07-23 |
2018-02-13 |
Ambrx, Inc. |
Polipéptidos G-CSF bovinos modificados y sus usos
|
|
EP3629022A1
(en)
|
2008-07-25 |
2020-04-01 |
Richard W. Wagner |
Protein screening methods
|
|
US20100129375A1
(en)
|
2008-09-10 |
2010-05-27 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
|
UA106731C2
(uk)
|
2008-09-26 |
2014-10-10 |
Амбркс, Інк. |
Модифіковані поліпептиди еритропоетину тварин та їх застосування
|
|
EP2331070A1
(en)
*
|
2008-09-26 |
2011-06-15 |
Phares Pharmaceutical Research N.V. |
Method of solubilising biologically active compounds
|
|
NZ592249A
(en)
*
|
2008-09-26 |
2013-03-28 |
Ambrx Inc |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
|
SG195542A1
(en)
|
2008-10-10 |
2013-12-30 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
|
NZ627111A
(en)
|
2008-11-26 |
2015-10-30 |
Amgen Inc |
Variants of activin iib receptor polypeptides and uses thereof
|
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
|
US20110312872A1
(en)
|
2008-12-22 |
2011-12-22 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
WO2010072740A2
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
|
|
EP2390261A4
(en)
|
2009-01-20 |
2012-11-14 |
Hanall Biopharma Co Ltd |
MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
|
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
US20120034650A1
(en)
|
2009-02-13 |
2012-02-09 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
|
DK3248610T3
(da)
|
2009-05-05 |
2024-01-15 |
Amgen Inc |
Fgf21-mutanter og anvendelser deraf
|
|
WO2010129600A2
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
|
IN2012DN00352A
(da)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
|
AU2010262927A1
(en)
|
2009-06-17 |
2012-01-19 |
Amgen Inc. |
Chimeric FGF19 polypeptides and uses thereof
|
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
|
WO2011046457A1
(en)
|
2009-10-16 |
2011-04-21 |
Auckland Uniservices Limited |
Anti-neoplastic uses of artemin antagonists
|
|
US8729058B2
(en)
|
2009-10-27 |
2014-05-20 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
|
ES2626000T3
(es)
|
2009-11-02 |
2017-07-21 |
University Of Washington |
Composiciones terapéuticas de nucleasas y métodos
|
|
US20130116182A1
(en)
|
2009-11-13 |
2013-05-09 |
Kathleen Pratt |
Factor VIII B Cell Epitope Variants Having Reduced Immunogenicity
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
WO2011066260A2
(en)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
AU2010341516B2
(en)
|
2009-12-21 |
2014-01-16 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
|
JP2013515081A
(ja)
|
2009-12-21 |
2013-05-02 |
アンブルックス，インコーポレイテッド |
修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
|
|
EP2525792A1
(en)
|
2010-01-19 |
2012-11-28 |
Medizinische Universität Wien |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
|
AU2011210825B2
(en)
|
2010-01-27 |
2017-02-02 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
|
US8778416B2
(en)
|
2010-02-10 |
2014-07-15 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
|
CA2789443C
(en)
|
2010-02-12 |
2016-09-13 |
Chimerix, Inc. |
Nucleoside phosphonate salts
|
|
EP2558497A2
(en)
|
2010-04-15 |
2013-02-20 |
Amgen Inc. |
Human fgf receptor and beta-klotho binding proteins
|
|
EP2561068A1
(en)
|
2010-04-19 |
2013-02-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
|
WO2011139709A2
(en)
|
2010-04-26 |
2011-11-10 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
|
US9320756B2
(en)
|
2010-05-07 |
2016-04-26 |
Centre National De La Recherche Scientifique |
UCP1 (thermogenin)—inducing agents for use in the treatment of a disorder of the energy homeostasis
|
|
CA2800065A1
(en)
|
2010-05-21 |
2011-11-24 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
|
MX347734B
(es)
|
2010-06-14 |
2017-05-11 |
Lykera Biomed Sa |
Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
|
|
CA2802635A1
(en)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides as active agents to stabilize biologic barriers
|
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
|
PE20140160A1
(es)
|
2010-08-17 |
2014-02-08 |
Ambrx Inc |
Polipeptidos de relaxina modificados y sus usos
|
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
|
CA2815181C
(en)
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
|
AU2011323508B2
(en)
|
2010-11-01 |
2017-04-27 |
Peptimed, Inc. |
Compositions of a peptide targeting system for treating cancer
|
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
|
ES2718849T3
(es)
|
2010-11-24 |
2019-07-04 |
Lexicon Pharmaceuticals Inc |
Anticuerpos contra notum pectinacetilesterasa
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
ES2847304T3
(es)
|
2011-01-17 |
2021-08-02 |
Lykera Biomed S A |
Anticuerpos contra la proteína S100P para el tratamiento y diagnóstico de cáncer
|
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
|
PT2667715T
(pt)
|
2011-01-27 |
2017-10-19 |
Neuren Pharmaceuticals Ltd |
Tratamento de perturbações do espetro do autismo utilizando o ácido glicil-l-2-metilpropil-l-glutâmico
|
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
|
BR112013023120A2
(pt)
|
2011-03-10 |
2017-09-19 |
Genentech Inc |
método de tratar uma disfunção associada com função de barreira vascular alterada em um sujeito, método de reduzir ou inibir função de barreira vascular em um sujeito em necessidade do mesmo e método de tratar uma disfunção que requer formação de novos vasos sanguíneos em um sujeito
|
|
MX2013011706A
(es)
|
2011-04-07 |
2014-04-25 |
Amgen Inc |
Proteinas novedosas de enlace a antigeno.
|
|
EP2694092B1
(en)
|
2011-04-08 |
2017-01-04 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
SI2704737T1
(en)
|
2011-04-29 |
2018-06-29 |
University Of Washington |
Therapeutic nucleosomal compositions and procedures
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
JP2014513981A
(ja)
|
2011-05-10 |
2014-06-19 |
アムジエン・インコーポレーテツド |
ＦＧＦＲ１とβ−ＫＬＯＴＨＯの相互作用を特異的に調節する化合物の同定方法
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
WO2012174064A1
(en)
|
2011-06-14 |
2012-12-20 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
WO2012174534A2
(en)
|
2011-06-17 |
2012-12-20 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
|
EP2744828A4
(en)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
|
|
CA2843369A1
(en)
|
2011-08-16 |
2013-02-21 |
Evotec (Munchen) Gmbh |
Markers for susceptibility to an inhibitor of an src-family kinase
|
|
CA2845357A1
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
|
BR112014006822B1
(pt)
|
2011-09-22 |
2021-05-18 |
Amgen Inc. |
Proteína de ligação ao antígeno cd27l, composição compreendendo uma proteína de ligação ao antígeno cd27l, ácido nucleico isolado, vetor de expressão, célula hospedeira recombinante procariótica, método de preparação de um conjugado de droga e anticorpo cd27l e uso de uma proteína de ligação ao antígeno cd27l
|
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun （Shanghai）Science & Technology Limited |
Compositions and methods for treating heart failure
|
|
WO2013056255A1
(en)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions for inhibiting tumor cell proliferation
|
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
|
EP2780040A1
(en)
|
2011-11-16 |
2014-09-24 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
EP2944628B1
(en)
|
2011-11-30 |
2017-01-04 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
|
US9376715B2
(en)
|
2011-12-09 |
2016-06-28 |
Roche Molecular Systems, Inc |
Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
|
|
US20150017157A1
(en)
|
2011-12-19 |
2015-01-15 |
Xoma (Us) Llc |
Methods for treating acne
|
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
KR20140125803A
(ko)
|
2012-01-26 |
2014-10-29 |
암젠 인크 |
성장 분화 인자 15(gdf-15) 폴리펩타이드들
|
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
WO2013172954A1
(en)
|
2012-05-17 |
2013-11-21 |
Ra Pharmaceuticals, Inc |
Peptide and peptidomimetic inhibitors
|
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
|
EP2866821B1
(en)
|
2012-07-02 |
2018-11-14 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
|
WO2014031649A1
(en)
|
2012-08-21 |
2014-02-27 |
Genesys Research Institute |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
CA2889298C
(en)
|
2012-11-30 |
2024-01-02 |
Anton Belousov |
Identification of patients in need of pd-l1 inhibitor cotherapy
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
SG11201505960VA
(en)
|
2013-02-01 |
2015-08-28 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
|
EP2970451A1
(en)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
US9474792B2
(en)
|
2013-03-15 |
2016-10-25 |
Amgen Inc. |
Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
|
|
PL2970449T3
(pl)
|
2013-03-15 |
2020-04-30 |
Amgen Research (Munich) Gmbh |
Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
|
EP2970470B1
(en)
|
2013-03-15 |
2019-12-04 |
Amgen Inc. |
Human pac1 antibodies
|
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
|
EP2970483A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
|
DK2984108T3
(en)
|
2013-04-09 |
2017-09-18 |
Lykera Biomed S A |
Anti-s100a7 antibodies for the treatment and diagnosis of cancer
|
|
EP2801370A1
(en)
|
2013-05-07 |
2014-11-12 |
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron |
Methods and compositions for the treatment of cancer
|
|
US10501803B2
(en)
|
2013-05-21 |
2019-12-10 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
|
JP6568052B2
(ja)
|
2013-05-22 |
2019-09-04 |
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． |
心不全を治療するためのニューレグリンの徐放
|
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
|
BR112015029643B1
(pt)
|
2013-05-30 |
2023-12-12 |
Kiniksa Phamaceuticals, Ltd |
Proteínas de ligação ao antígeno de receptor de oncostatina m, seu método de preparação e seu uso, composições farmacêuticas, ácido nucleico isolado, vetor de expressão e célula hospedeira procariótica recombinante
|
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
|
JP6267792B2
(ja)
|
2013-06-28 |
2018-01-24 |
アムジエン・インコーポレーテツド |
ホモ接合性家族性高コレステロール血症の治療方法
|
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
|
AU2014296107B2
(en)
|
2013-07-31 |
2018-07-26 |
Amgen Inc. |
Growth differentiation factor 15 (GDF-15) constructs
|
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US11427627B2
(en)
|
2013-09-05 |
2022-08-30 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
|
|
CA2924109A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
|
MX348980B
(es)
|
2013-09-16 |
2017-07-05 |
Cemm-Forschungszentrum Für Molekulare Medizin Gmbh |
Calreticulina mutante para la diagnosis de malignidades mieloides.
|
|
EP3521431A1
(en)
|
2013-09-25 |
2019-08-07 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
|
ES2845924T3
(es)
|
2013-10-15 |
2021-07-28 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
|
|
AU2014337385B2
(en)
|
2013-10-15 |
2020-04-30 |
The Scripps Research Institute |
Chimeric antigen receptor T cell switches and uses thereof
|
|
US20160235810A1
(en)
|
2013-10-18 |
2016-08-18 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
|
US10988745B2
(en)
|
2013-10-31 |
2021-04-27 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
|
CA2933701C
(en)
|
2013-12-18 |
2022-05-31 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
US10532083B2
(en)
|
2014-02-13 |
2020-01-14 |
Technische Universität München |
Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
|
|
RU2693430C2
(ru)
|
2014-02-20 |
2019-07-02 |
Аллерган, Инк. |
Антитела к компоненту комплемента с5
|
|
CA2939586A1
(en)
|
2014-02-27 |
2015-09-03 |
Allergan, Inc. |
Complement factor bb antibodies
|
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
|
US20170073690A1
(en)
|
2014-05-15 |
2017-03-16 |
CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH |
Antagonists of slc38a9 and their use in therapy
|
|
US20170119851A1
(en)
|
2014-05-19 |
2017-05-04 |
Novartis Ag |
Methods of treating anorexia
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
SG11201610432UA
(en)
|
2014-06-13 |
2017-01-27 |
Santa Maria Biotherapeutics Inc |
Formulated receptor polypeptides and related methods
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
US11661462B2
(en)
|
2014-07-31 |
2023-05-30 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody contructs
|
|
WO2016025401A1
(en)
*
|
2014-08-09 |
2016-02-18 |
Avanti Polar Lipids, Inc. |
Oral composition for delivery of drugs and other substances
|
|
AU2015301753B2
(en)
|
2014-08-12 |
2021-04-08 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
EP3183346A4
(en)
|
2014-08-22 |
2018-10-24 |
Auckland Uniservices Limited |
Channel modulators
|
|
SG11201701402QA
(en)
|
2014-08-27 |
2017-03-30 |
Peptimed Inc |
Anti-tumor compositions and methods
|
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
|
EA036697B1
(ru)
|
2014-10-24 |
2020-12-09 |
Бристол-Майерс Сквибб Компани |
Модифицированные полипептиды fgf-21 и их применение
|
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
|
JP7264592B2
(ja)
|
2015-01-26 |
2023-04-25 |
ザ ユニバーシティー オブ シカゴ |
ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
|
|
US20180170992A1
(en)
|
2015-01-26 |
2018-06-21 |
The University Of Chicago |
CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
|
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
CA2976593A1
(en)
|
2015-02-23 |
2016-09-01 |
Seagull Therapeutics Sas |
Non-natural semaphorins 3 and their medical use
|
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
UA126270C2
(uk)
|
2015-04-10 |
2022-09-14 |
Емджен Інк. |
Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
|
|
WO2016164937A2
(en)
|
2015-04-10 |
2016-10-13 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
WO2016168773A2
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
EA201792193A1
(ru)
|
2015-04-17 |
2018-05-31 |
Эмджен Рисерч (Мьюник) Гмбх |
Конструкции биспецифического антитела для cdh3 и cd3
|
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
|
CN107921098A
(zh)
|
2015-06-17 |
2018-04-17 |
加州生物医学研究所 |
修饰的治疗剂及其组合物
|
|
WO2017007955A1
(en)
|
2015-07-07 |
2017-01-12 |
The Research Foundation For The State University Of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
AU2016332062A1
(en)
|
2015-10-01 |
2018-04-26 |
Amgen Inc. |
Treatment of bile acid disorders
|
|
CN108350077A
(zh)
|
2015-11-03 |
2018-07-31 |
糖模拟物有限公司 |
产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
|
|
JP7100362B2
(ja)
|
2015-11-13 |
2022-07-13 |
ドメイン・セラピューティクス |
グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換三環式１，４－ベンゾジアゼピノン誘導体
|
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
|
ES2898704T3
(es)
|
2015-12-09 |
2022-03-08 |
Univ Wien Med |
Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer
|
|
SG11201805255TA
(en)
|
2015-12-23 |
2018-07-30 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
|
KR20190031425A
(ko)
|
2016-01-15 |
2019-03-26 |
함부르크대학교 |
O-람노실 잔기를 보유하는 플라보노이드-유형 화합물
|
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究（慕尼黑）公司 |
包含雙特異性抗體建構物之醫藥組合物
|
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
SI3411402T1
(sl)
|
2016-02-03 |
2022-03-31 |
Amgen Research (Munich) Gmbh |
Konstrukti bispecifičnih protiteles BCMA in CD3, ki aktivirajo T celico
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
CA3013988A1
(en)
|
2016-02-15 |
2017-08-24 |
Cemm-Forschungszentrum Fur Molekulare Medizin Gmbh |
Taf1 inhibitors for the therapy of cancer
|
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
|
EP3439636B1
(en)
*
|
2016-04-05 |
2023-06-07 |
The Research Foundation for the State University of New York |
Phosphoserine containing compositions for immune tolerance induction
|
|
WO2017178820A1
(en)
|
2016-04-15 |
2017-10-19 |
Oxford University Innovation Limited |
Adenosine receptor modulators for the treatment of circadian rhythm disorders
|
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
EP3269734A1
(en)
|
2016-07-15 |
2018-01-17 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Methods and compositions for the treatment of cancer
|
|
WO2018013924A1
(en)
|
2016-07-15 |
2018-01-18 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
|
WO2018024654A1
(en)
|
2016-08-02 |
2018-02-08 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
|
AU2017310412A1
(en)
|
2016-08-08 |
2019-02-21 |
Amgen Inc. |
Method of improving connective tissue attachment using anti-sclerostin antibodies
|
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
|
KR102613430B1
(ko)
|
2016-10-19 |
2023-12-18 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
|
AU2017359288A1
(en)
|
2016-11-14 |
2019-05-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
|
|
EP3548488A1
(en)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center for Personalized Cancer Medicine GmbH |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
|
|
CA3049110A1
(en)
|
2017-01-06 |
2018-07-12 |
Abl Bio Inc. |
Anti-.alpha.-syn antibody and use thereof
|
|
CN110494445B
(zh)
|
2017-01-06 |
2023-10-20 |
Abl生物公司 |
抗α-SYN抗体及其用途
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
EP3580232B1
(en)
|
2017-02-08 |
2023-09-20 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
|
US11021529B2
(en)
|
2017-03-03 |
2021-06-01 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
|
US11918650B2
(en)
|
2017-05-05 |
2024-03-05 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
|
US11180518B2
(en)
|
2017-05-12 |
2021-11-23 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
|
WO2018206820A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
US20210087286A1
(en)
|
2017-06-20 |
2021-03-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
EP3655005A4
(en)
|
2017-07-19 |
2021-04-28 |
Auckland Uniservices Limited |
CYTOCINE MODULATION
|
|
JP2020530453A
(ja)
|
2017-08-09 |
2020-10-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
アルブミン結合ペプチド結合体及びその方法
|
|
EP3684811A2
(en)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multiple specificity binders of cxc chemokines and uses thereof
|
|
EP3672986A1
(en)
|
2017-08-22 |
2020-07-01 |
Sanabio, LLC |
Soluble interferon receptors and uses thereof
|
|
KR20200055037A
(ko)
|
2017-09-19 |
2020-05-20 |
메사추세츠 인스티튜트 오브 테크놀로지 |
키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
|
|
EA202090581A1
(ru)
|
2017-10-04 |
2020-08-31 |
Амген Инк. |
Продукты слияния транстиретина и иммуноглобулина
|
|
WO2019089365A1
(en)
|
2017-10-30 |
2019-05-09 |
Enterin Laboratories, Inc. |
New squalamine solid forms and methods of making the same
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019110139A1
(en)
|
2017-12-05 |
2019-06-13 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
|
CA3082507A1
(en)
|
2017-12-11 |
2019-06-20 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
JP2021506851A
(ja)
|
2017-12-19 |
2021-02-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
抗原−アジュバントカップリング試薬および使用の方法
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
AU2019235842B2
(en)
|
2018-03-14 |
2022-02-03 |
Surface Oncology, Inc. |
Antibodies that bind CD39 and uses thereof
|
|
SG11202008707YA
(en)
|
2018-03-22 |
2020-10-29 |
Surface Oncology Inc |
Anti-il-27 antibodies and uses thereof
|
|
BR112020020080A2
(pt)
|
2018-03-30 |
2021-01-05 |
Amgen Inc |
Variantes de anticorpos c-terminais
|
|
US20210163406A1
(en)
|
2018-04-06 |
2021-06-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
|
|
MX2020010552A
(es)
|
2018-04-06 |
2020-12-11 |
Zilentin AG |
Derivados de bumetanida para el tratamiento de la hiperhidrosis.
|
|
BR112020020823A2
(pt)
|
2018-04-09 |
2021-01-19 |
Amgen Inc. |
Proteínas de fusão do fator de diferenciação do crescimento 15
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
CN112105733A
(zh)
|
2018-04-19 |
2020-12-18 |
查美特制药公司 |
合成rig-i样受体激动剂
|
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
|
US20200109195A1
(en)
|
2018-05-21 |
2020-04-09 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
BR112021003843A2
(pt)
|
2018-08-28 |
2021-05-25 |
Ambrx, Inc. |
biconjugados de folato de anticorpo anti-cd3 e seus usos
|
|
US12049485B2
(en)
|
2018-09-11 |
2024-07-30 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
|
WO2020068261A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
AU2019407650B2
(en)
|
2018-12-17 |
2022-10-27 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
|
WO2020142740A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
|
US11235032B2
(en)
|
2019-01-23 |
2022-02-01 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
|
BR112021015832A2
(pt)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
|
|
TW202102542A
(zh)
|
2019-03-19 |
2021-01-16 |
瓦爾希伯倫私人腫瘤研究基金會 |
用於治療癌症的聯合療法
|
|
US20200345853A1
(en)
|
2019-03-20 |
2020-11-05 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
WO2020252442A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
WO2020263399A1
(en)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CA3140208A1
(en)
|
2019-07-08 |
2021-01-14 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
|
EP4004041A1
(en)
|
2019-07-26 |
2022-06-01 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
|
JP2022544549A
(ja)
|
2019-08-12 |
2022-10-19 |
ピュリノミア バイオテック， インコーポレイテッド |
Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
|
|
CA3150441A1
(en)
|
2019-08-13 |
2021-02-18 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
|
BR112022002351A2
(pt)
|
2019-09-16 |
2022-07-19 |
Surface Oncology Inc |
Composições e métodos de anticorpo anti-cd39
|
|
EP4034559A1
(en)
|
2019-09-25 |
2022-08-03 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
AU2020360709B2
(en)
|
2019-10-02 |
2024-02-15 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
|
WO2021074414A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
EP4048795A1
(en)
|
2019-10-23 |
2022-08-31 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
|
EP4048405A2
(en)
|
2019-10-24 |
2022-08-31 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
MX2022005914A
(es)
|
2019-11-19 |
2022-08-04 |
Modag Gmbh |
Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
|
|
JP2023507115A
(ja)
|
2019-12-17 |
2023-02-21 |
アムジエン・インコーポレーテツド |
治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト
|
|
BR112022011749A2
(pt)
|
2020-01-06 |
2022-08-30 |
Vaccinex Inc |
Anticorpos anti-ccr8 e seus usos
|
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
|
IL296099A
(en)
|
2020-03-11 |
2022-11-01 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and methods of using them
|
|
EP4121459A1
(en)
|
2020-03-19 |
2023-01-25 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
US20230226057A1
(en)
|
2020-06-25 |
2023-07-20 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
|
WO2022006153A1
(en)
|
2020-06-29 |
2022-01-06 |
Resolve Therapeutics, Llc |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
|
KR20230058081A
(ko)
|
2020-08-26 |
2023-05-02 |
스캔셀 리미티드 |
인간 IgG1의 변형된 FC 영역과 적어도 하나의 이종 항원을 포함하는 폴리펩티드를 암호화하는 핵산
|
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
|
CA3194868A1
(en)
|
2020-10-16 |
2022-04-21 |
Georg Winter |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
IL305301A
(en)
|
2021-02-19 |
2023-10-01 |
Us Health |
Single domain antibodies neutralizing SARS CoV-2
|
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス，インコーポレイテッド |
抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
|
|
BR112023020538A2
(pt)
|
2021-04-07 |
2024-01-23 |
Tolremo Therapeutics Ag |
Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
|
|
CA3217865A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
EP4334348A1
(en)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
|
US20230022990A1
(en)
|
2021-05-14 |
2023-01-26 |
Claris Biotherapeutics, Inc. |
Compositions of growth factor for the treatment of eye disease
|
|
CA3230815A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long ot syndrome
|
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|
|
AU2022381918A1
(en)
|
2021-11-03 |
2024-06-13 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
|
WO2024089013A1
(en)
|
2022-10-25 |
2024-05-02 |
Peptomyc, S.L. |
Combination therapy for the treatment of cancer
|
|
WO2024121796A1
(en)
|
2022-12-07 |
2024-06-13 |
Fondazione Matilde Tettamanti E Menotti De Marchi Onlus |
Methods for generating genetically modified cytokine induced killer (cik) cells
|